CLAIM #22715 · EMR (EMR) · 2024Q2 earnings call · May 8, 2024 · due Sep 30, 2024
“So flat Q3, sequentially up in Q4.”
Ram Krishnan · COO
In context
“n our process and hybrid business is still intact. And as certainly we go through the summer and approach the fall outages and STOs and turnaround opportunities, we look at, at least from this point in time, rather positively as well. So that's what's going to play into this as we go through the second half and, hence, gives us confidence also on that exit rate on orders for the year. C. Stephen Tusa: And then just one last one on NATI, I don't -- I haven't done the math on this 3Q guide. But is that down sequentially and then up sequentially in the fourth quarter? It looks to me like the revenue run rate now, at least for the second half versus 2Q, is basically flattish at around $370 million or something like that. Is that the right construct for NATI in the second half? Ram Krishnan: So flat Q3, sequentially up in Q4. C. Stephen Tusa: Yes. So it's bottomed, the revenues have bottomed there? Ram Krishnan: Yes. Operator: The next question is from Joe O'Dea, Wells Fargo. Joseph O'Dea: Can you dig in a little bit on the growth trends in Measurement & Analytical and Final Control? I mean, it seems like Measurement & Analytical organic, low double digits, maybe even touch low-teens this year, Final Control, mid-single digits. Just some of the differences in those growth rates, what you're seeing on the measurement side versus what you're seeing on the Final Control side. Ram Krishnan: So measurement solutions this year, you're spot on there, it's going to grow faster than Final Control primarily because that was the business that suffered the most from our backlog build due to lead times. Those -- that”
Verify independently
SEC filings for EMR ↗ · Claim quote is verbatim from the 2024Q2 earnings call.